HC Wainwright Has Optimistic Outlook of CMPX FY2028 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Research analysts at HC Wainwright raised their FY2028 earnings per share (EPS) estimates for shares of Compass Therapeutics in a report released on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.94 for the year, up from their prior estimate of $0.85. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share.

Other research analysts also recently issued reports about the company. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $5.00 to $4.00 in a research note on Friday. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Compass Therapeutics Trading Down 13.2 %

Shares of CMPX stock opened at $1.38 on Thursday. The company has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34. The business’s 50 day moving average is $1.75 and its two-hundred day moving average is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Opaleye Management Inc. acquired a new stake in Compass Therapeutics in the 1st quarter valued at about $6,277,000. CM Management LLC grew its stake in Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after purchasing an additional 185,000 shares in the last quarter. Ground Swell Capital LLC acquired a new position in Compass Therapeutics in the second quarter worth about $124,000. Barclays PLC grew its position in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.